ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / BWAY / financials
SSII (30) CERS (30) DCTH (62) NPCE (23) ⌘ Pro Terminal →

BrainsWay Ltd. (BWAY) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$11.36 -4.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.24

BrainsWay Ltd. (BWAY) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $478.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BWAY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BWAY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, BrainsWay Ltd. (NASDAQ: BWAY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $11.36 (-4.78% 1D, market cap $478.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BWAY ranks #345 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BWAY compare to SSII and CERS in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), BWAY carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SSII (SS Innovations International Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M) and CERS (Cerus Corporation) posts a E grade (30/100 RQD, P/E N/A, ROIC -15.5%, cap $491.7M). Among the 5-stock peer group, BWAY leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BWAY?
▼

For BrainsWay Ltd. (BWAY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #345 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.24 (-1.05%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D
Cash (12)Whales (6)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.9% Base Target
$18 Bull$11 Base$8 Bear
📬 FREE BWAY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BWAY)Realized 20D OHLCV Swing Band: ±8%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY BWAY SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($13.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$11.46+4.6% Next Q
Q2 (-2Q)
52
Grade C-$11.99-6.5% Next Q
Q3 (-1Q)
50
Grade C-$11.21+1.3% Next Q
Current
47
Grade D$11.36-5.9% Hist 90D α
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BWAY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BWAY currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.90) and Max Pain ($11.93) forces dealer call-delta covering toward $18.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BWAY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BWAY Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How BWAY Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$13.4M (0.3% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $1.08B (27%)OpEx (R&D/SG&A) $998.4MNet Profit$865.3M (21.6%)Tax/Other $216.3M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BWAY)

  • ✓Walkthrough of BWAY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BWAY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.82%🛡️ HOLDING TREND SUPPORT
2026-11-02O $11.37H $11.93L $11.36C $11.36VOL 121.7K
RES: $17.45SUP: $10.83SMA50: $12.90SMA200: $13.92
$17.92$15.75$13.59$11.42$9.25RES $17.45SUP $10.83$11.362026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BWAY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BWAY Butterfly Map → + Track BWAY →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BWAY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BWAY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BWAY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BWAY)

Health Care Rank #345 of 1016 ⚔️ SSII vs BWAY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BWAY vs. SSII, CERS, DCTH, NPCE)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BrainsWay Ltd. (BWAY) ranks #345 by composite RQD confidence (47/100, grade D) and #461 by equity capitalization ($478.7M). Within this direct 5-issuer industry benchmark cohort, BWAY leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with BWAY at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BWAY ACTIVE
BrainsWay Ltd.
D 47/100 — — — -4.78% $478.7M Benchmark Subject
SSII
SS Innovations International Inc.
E 30/100 — 46.0% -18.5% -1.26% $477.2M /ssii-vs-bway →
CERS
Cerus Corporation
E 30/100 — — -15.5% -6.56% $491.7M /cers-vs-bway →
DCTH
Delcath Systems Inc.
C 62/100 — 86.2% 0.8% -4.10% $508.0M /dcth-vs-bway →
NPCE
Neuropace Inc.
E 23/100 — 77.2% -23.0% -5.46% $446.6M /npce-vs-bway →

2. BWAY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

BrainsWay Ltd. (BWAY) operates in Medical/Dental Instruments (Health Care) with an equity capitalization of $478.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. BWAY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BWAY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, BrainsWay Ltd. (NASDAQ: BWAY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $11.36 (-4.78% 1D, market cap $478.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BWAY ranks #345 in composite RQD confidence.

How does BWAY compare to SSII and CERS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BWAY carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SSII (SS Innovations International Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M) and CERS (Cerus Corporation) posts a E grade (30/100 RQD, P/E N/A, ROIC -15.5%, cap $491.7M). Among the 5-stock peer group, BWAY leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BWAY?

For BrainsWay Ltd. (BWAY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #345 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BWAY trading relative to its 50-day, 200-day, and 52-week technical levels?

BWAY last traded at $11.36 (-4.78% on volume of 123,884 shares), positioning the stock -11.94% below its 50-day simple moving average ($12.90) and -18.39% below its 200-day simple moving average ($13.92). Across its 52-week range of $7.14 to $17.40, BWAY sits at the 41.1% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±8.0% ($10.45 to $12.27).

BWAY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is BrainsWay Ltd. (BWAY)?

In Trailing 12 Months, BWAY converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $13.4M in free cash flow (0.3% FCF margin).

Direct Sub-Reports: BWAY RQD Cockpit BWAY 12M Forecast BWAY Earnings & Move BWAY Dividends & DRIP BWAY Insiders & 13F BWAY Whale Options BWAY Profit Sankey BWAY News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BWAY — BrainsWay Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:16:01Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BWAY scores 47 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 6/20 (institutional accumulation and options positioning), Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 7/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The lowest-scoring pillars, Whale 13F Flow and Macro Regime Fit, indicate weak institutional conviction and no differentiated sector tailwind per the rating. The strongest pillar, Forensic Balance Sheet, reflects a balance sheet that is comparatively sound on the metrics provided, though the 0% ROIC and 0% FCF yield in the Fundamental Cash Engine pillar show that the business is not currently generating returns on invested capital or free cash flow per the source data. For a prospective investor, the rating frames the stock as one where the balance sheet offers some support while cash-generation and institutional-flow signals point to caution; the rating's own verdict is distribution-warning in tone. This is an analytical summary of the rating, not a recommendation.

Recent Catalysts & News Wire Analysis

  • Market wire (YELLOW): A Stocktwits item and an HWG Holdings LP new-stake item (MarketBeat) both reference institutional positioning; the source does not specify position size.
  • Catalyst (GREEN): A Stock Titan item reports a Southern California provider ordering multiple BrainsWay brain stimulation systems.
  • Catalyst (GREEN): A Stock Titan item reports a partner linked to 27 clinics teaming with BrainsWay on mental-health treatment access.
  • Catalyst (GREEN): A high-volume item reports the stock rising 5.68% to $12.09, reclaiming a key pivot level. The source headline's summary field contains an unrelated URL instead of description text.
  • Market wire (YELLOW): A MarketBeat item reports an HC Wainwright "Buy" rating on NASDAQ:BWAY.
  • Risk watch: The price change of 4.93% and volume of 121,745 are the only trading data points; the source does not establish whether moves are sustained.
  • Proprietary signals: None. The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals.

Open Questions

  • What are BrainsWay's revenue, operating income, and net income for the most recent reported periods, given that the financials section is empty and margins are reported as 0%?
  • What products does BrainsWay sell and to which customer segments, and how much of revenue comes from the brain stimulation systems referenced in the news?
  • Why are P/E, forward P/E, EV/EBITDA, and EPS absent, and what is the company's current earnings profile?
  • What are the size and direction of the institutional and insider positions behind the Whale 13F Flow and Insider Conviction pillar scores?
  • What analyst price targets and consensus ratings exist beyond the single HC Wainwright "Buy" reference?

BWAY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BrainsWay Ltd. (BWAY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BWAY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BWAY Bull vs. Bear Conversation Board — What's Your Call at $11.36?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BWAY 🐻 50% BEARISH CONVICTION
1. Pick Your Side on BWAY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $12.88 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BWAY (D • RQD 47/100) a Buy at $11.93?

Welcome to the BWAY (BrainsWay Ltd.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.78 (-18.0%)
Spot @ $11.93

Pump the brakes on BWAY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BWAY, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless BrainsWay Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $13.84 (+16.0%)
Spot @ $11.93

BWAY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BWAY, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $11.93 (52-wk range $7.14 - $17.40), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%